StockData
Revolution Medicines, Inc. logo

Revolution Medicines, Inc. (RVMD) stock

RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$162.69−4.18 (-2.50%)

Close on Nov 17, 2026Market cap $34.87BP/E –Yield –

Revolution Medicines enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Revolution Medicines's enterprise value was $34.78B on Nov 11, 2026, against $12.82B a year earlier. Over the last 5 years it ranged from $741.63M to $40.10B, with a median of $4.62B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$34.78B+163.9%
2025Dec 31, 2025$13.18B+127.7%
2024Dec 31, 2024$5.79B+148.8%
2023Dec 29, 2023$2.33B+61.9%
2022Dec 30, 2022$1.44B+15.4%
2021Dec 31, 2021$1.25B-42.3%
2020Dec 31, 2020$2.16B–

More Revolution Medicines figures

See a number that looks wrong?